RxDoctor Payments Data

Robert Horth, MD

Cardiovascular Disease · Plymouth, WINPI 1699768259

Payments from drug & device makers

$868in general payments, 2019–2025

Across 44 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$183
  • Amgen$126
  • Lexicon Pharmaceuticals, Inc.$115
  • Boehringer Ingelheim$72
  • E.r. Squibb & Sons, L.L.C.$66
  • Novo Nordisk$62
  • plus $244 from 9 others

What the payments were for

  • Food & beverage$868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$868 in reported general payments places this provider in the 45th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$112,964
Medicare patients
1,085
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$195,229
EntrestoSacubitril/Valsartan69$86,112
XareltoRivaroxaban38$48,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$34,574
Repatha SureclickEvolocumab47$34,428
JardianceEmpagliflozin28$34,364
OzempicSemaglutide23$24,126
Atorvastatin Calcium334$3,377
Metoprolol Succinate154$2,338
Ezetimibe155$2,325
Losartan Potassium193$1,951
Colestipol Hcl11$1,931
Arnuity ElliptaFluticasone Furoate11$1,799
Pantoprazole Sodium117$1,777
Digoxin71$1,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$195,229210 claims
NovartisEntresto$183$86,11269 claims
Johnson & JohnsonXarelto$44$48,34438 claims
GSKTrelegy Ellipta, Arnuity Ellipta$13$36,37358 claims
Boehringer IngelheimJardiance$72$34,36428 claims
Novo NordiskOzempic$62$24,12623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Plymouth

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →